Development of Integrated In-Process Monitoring to Enable High Throughput Cell and Gene Therapy Manufacturing

Ori正在开发下一代商业化生产细胞和基因疗法（CGT）的解决方案。CAR-T细胞疗法是CGT的一种，已被证明在治疗危及生命的疾病（包括血癌）方面非常有效，在实体瘤方面也很有希望；然而，这些疗法的制造方式存在着巨大的问题。这些问题导致患者获得这些可能挽救生命的疗法的机会有限。该项目的重点是开发技术，使治疗能够以最高的效率和最高的质量，以最快的速度进行。这将解决目前制造CGT，特别是CAR-T细胞疗法所面临的巨大挑战。Ori的愿景是使患有侵袭性癌症和其他严重疾病的患者能够获得这些挽救生命的疗法。Ori技术将通过改进生产方式和降低成本来实现这一目标，目前成本非常高（每治疗剂量约为17.5万英镑）。

Ori are developing the next generation of solutions for manufacturing cell and gene therapies (CGT) at commercial scale.CAR-T cell therapies are a type of CGT that have been shown to be incredibly effective in treating life-threatening conditions, including blood cancers and holds great hope in solid tumours; however, there are huge problems in the way these therapies are manufactured.These problems are leading to patients having limited access to these potentially life-saving therapies. This project focusses on the development of technology that will allow therapies to be made with maximum efficiency and to the highest quality, with the fastest throughput. This will address huge challenges currently encountered with manufacturing CGT and specifically, CAR-T cell therapies.Ori's vision is to enable access to these life-saving therapies for patients suffering from aggressive forms of cancer and other serious conditions. Ori technology will enable this access by improving how manufacturing is carried out and reducing the cost, which is currently extremely high (about £175K per therapy dose made).